NeuroMetrix Inc
Change company Symbol lookup
Select an option...
NURO NeuroMetrix Inc
OTTW Ottawa Savings Bancorp Inc
HMC Honda Motor Co Ltd
PAVMZ PAVmed Series Z Equity Warrants Exp 30 Apr 2024 *W EXP 04/30/2024
FFBW Ffbw Inc
CIB Bancolombia SA
TARA Protara Therapeutics Inc
SLAMU Slam Corp
SY So-Young International Inc
BHR Braemar Hotels & Resorts Inc

Health Care : Health Care Equipment & Supplies | Small Cap Value
Company profile

NeuroMetrix, Inc. develops and commercializes health care products that utilize non-invasive neurostimulation. The Company is engaged in the designing, building and marketing of medical devices that stimulate nerves and analyze nerve response for diagnostic and therapeutic purposes. It has two principal product categories, which includes point-of-care neuropathy diagnostic tests and wearable neurostimulation devices. Its products include DPNCheck, Quell and ADVANCE System. DPNCheck is a quantitative nerve conduction test that is used to evaluate peripheral neuropathies, such as Diabetic peripheral neuropathy (DPN). Quell a wearable device for symptomatic relief and management of chronic pain. ADVANCE System is a platform for the performance of nerve conduction studies. DPNCheck customers include managed care organizations, endocrinologists, podiatrists and primary care physicians. ADVANCE System customers include occupational health, primary care, internal medicine and many others.

Closing Price
Day's Change
-0.04 (-1.09%)
B/A Size
Day's High
Day's Low

10-day average volume:

Children's Place stock plunges after earnings miss, sales guidance cut

7:51 am ET May 19, 2022 (MarketWatch)

Children's Place Inc. (PLCE) shares slumped 13.2% in Thursday premarket trading after it reported first-quarter earnings and sales that missed expectations and cut its outlook. The kids apparel retailer posted net income of $19.8 million, or $1.43 per share, down from $45.2 million, or $3.01 per share, last year. Adjusted EPS of $1.05 missed the FactSet consensus for $1.43. Sales of $362.4 million were down from $435.5 million and also missed the FactSet consensus for $400.4 million. Comparable sales fell 16.9%. "Our Q1 results were negatively impacted by several factors, the largest being lapping the unprecedented stimulus released into the economy in March of 2021," said Chief Executive Jane Elfers in a statement. March sales were down 35%. "We also believe that the combination of the unseasonably cold weather that lasted through the end of the quarter in most of our key markets, and the unprecedented levels of inflation, particularly with respect to gasoline and food prices, negatively impacted our Q1 results." The company's Gymboree merchandise will be coming to Inc. (AMZN) in July. For the year, the company now expects a mid-single digit sales decline. The FactSet consensus is for sales of $1.9 billion, suggesting a 0.8% drop. Children's Place stock is down 45.5% for the year to date.

-Tonya Garcia


(END) Dow Jones Newswires

May 19, 2022 07:51 ET (11:51 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.